financetom
Business
financetom
/
Business
/
PAR Technology to Offer $100 Million Convertible Senior Notes due 2030
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PAR Technology to Offer $100 Million Convertible Senior Notes due 2030
Jan 21, 2025 7:30 AM

10:08 AM EST, 01/21/2025 (MT Newswires) -- PAR Technology ( PAR ) said Tuesday it plans to offer $100 million total principal amount of convertible senior notes due 2030 in a private offering.

The company also intends to provide the initial purchaser a 13-day option to buy up to an additional $15 million of notes.

PAR said it plans to use the net proceeds from the offering for the full repayment of its $90 million principal amount outstanding of the term loan under its credit deal with Blue Owl Capital (OBDC), and the remaining net proceeds for general corporate purposes.

The notes will not be redeemed before Jan. 20, 2028, at the company's discretion, it said.

Shares of PAR were down 6.4% in recent Tuesday trading.

Price: 68.55, Change: -4.65, Percent Change: -6.35

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Revance Therapeutics, Crown Laboratories Extend Merger Date Amid Commercialization Dispute
Revance Therapeutics, Crown Laboratories Extend Merger Date Amid Commercialization Dispute
Oct 18, 2024
12:25 PM EDT, 10/18/2024 (MT Newswires) -- Revance Therapeutics ( RVNC ) said Friday it has agreed with Crown Laboratories to further extend the deadline for Crown to acquire all outstanding Revance shares at $6.66 apiece in a tender offer, amid ongoing dispute with Teoxane. Revance is still in discussions with Teoxane regarding claims that it breached a 2020 distribution...
FDA approves Astellas' gastric cancer therapy
FDA approves Astellas' gastric cancer therapy
Oct 18, 2024
Oct 18 (Reuters) - The U.S. Food and Drug Administration approved Astellas' gastric cancer therapy, the health regulator's website showed on Friday. ...
Update: Intuitive Surgical Shares Rise After Q3 Earnings, Revenue Beat
Update: Intuitive Surgical Shares Rise After Q3 Earnings, Revenue Beat
Oct 18, 2024
12:28 PM EDT, 10/18/2024 (MT Newswires) -- (Updates with latest stock movement in the headline and first paragraph.) Intuitive Surgical ( ISRG ) shares rose over 8% in recent trading Friday, a day after posting higher Q3 results, beating market expectations. The company reported Q3 non-GAAP earnings late Thursday of $1.84 per diluted share, up from $1.46 a year earlier....
Update: United States Cellular Shares Jump Following Agreement to Sell Certain Spectrum Licenses to Verizon for $1 Billion
Update: United States Cellular Shares Jump Following Agreement to Sell Certain Spectrum Licenses to Verizon for $1 Billion
Oct 18, 2024
12:21 PM EDT, 10/18/2024 (MT Newswires) -- (Updates with United States Cellular's ( USM ) latest stock move in headline and first paragraph, and Verizon's stock move in the last paragraph.) United States Cellular ( USM ) shares jumped nearly 11% in recent Friday trading after the company said it has agreed to sell a portion of its retained spectrum...
Copyright 2023-2026 - www.financetom.com All Rights Reserved